Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 157212-55-0 | Product Number: B5118
Bosentan Monohydrate
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 4-(tert-Butyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide Monohydrate
- 4-tert-Butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzenesulfonamide Monohydrate
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 25MG |
₩133,200
|
11 | 35 | Contact Us | |
| 100MG |
₩405,200
|
37 | 0 | Contact Us |
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
| Product Number | B5118 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__7H__2__9N__5O__6S·H__2O = 569.64 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image), 25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 157212-55-0 |
| Related CAS RN | 147536-97-8 |
| Reaxys Registry Number | 9031515 |
| PubChem Substance ID | 354334055 |
| Merck Index (14) | 1353 |
| MDL Number | MFCD09751188 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Elemental analysis(Nitrogen) | 11.60 to 12.90 % |
| Water | 2.5 to 4.0 % |
Properties (reference)
| Solubility in water | Insoluble |
| Solubility (soluble in) | Ethanol |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
Transport Information:
| H.S.code* | 2935.90-000 |
Application
Bosentan: A Dual Endothelin Receptor Antagonist with Affinity for Both ETA and ETB Receptors
Endothelin-1 (ET-1) is a peptide that constricts pulmonary blood vessels and raise blood pressure. Two ET-1 receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The actions of ETA would be vasoconstriction and cell proliferation, while the actions of ETB would be vasodilatation, antiproliferation, and ET-1 clearance. Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A and B (ETA and ETB) receptors. At one time, the anti-fibrotic potential of bosentan was interested. For your reference, ambrisentan [A2966] is a selective ETA receptor antagonist. (The product is for research purpose only.)
References
- Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
- Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan)
- Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo: Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist
- Clinical pharmacology of bosentan, a dual endothelin receptor antagonist (a review)
- Role of endothelin in fibrosis and anti-fibrotic potential of bosentan (a review)
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.